

Semra Paydas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9403772/publications.pdf>

Version: 2024-02-01

231
papers

3,803
citations

159358

30
h-index

174990

52
g-index

235
all docs

235
docs citations

235
times ranked

4816
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Effectiveness of Combined Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with Postmastectomy Lymphedema: A Randomized Controlled Trial. <i>Lymphatic Research and Biology</i> , 2022, 20, 175-184.	0.5	2
2	The effect of <i>Paraoxonase</i> gene polymorphisms and paraoxonase enzyme activity on Non-Hodgkin lymphoma. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2022, , 1-14.	0.4	0
3	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. <i>Cancer Investigation</i> , 2022, 40, 199-209.	0.6	1
4	GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor. <i>European Journal of Mass Spectrometry</i> , 2022, 28, 12-24.	0.5	1
5	Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. <i>Journal of Chemotherapy</i> , 2022, , 1-8.	0.7	0
6	Jugular Paraganglioma Presenting With A Tumor Thrombus Extending From Posterior Fossa To Right Atrium And Multiple Skeletal Metastases. <i>Current Medical Imaging</i> , 2022, 18, .	0.4	0
7	Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. <i>Archives of Medical Science</i> , 2021, 17, 920-927.	0.4	0
8	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. <i>European Urology Focus</i> , 2021, 7, 1061-1066.	1.6	8
9	The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 249-255.	0.6	6
10	Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2145-2152.	1.2	4
11	Sarcoid-like reaction in cases treated by checkpoint inhibitors. <i>Medical Oncology</i> , 2021, 38, 29.	1.2	6
12	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	6.3	441
13	IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. <i>Leukemia Research</i> , 2021, 102, 106519.	0.4	1
14	Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas. <i>Ginekologia Polska</i> , 2021, 92, 278-283.	0.3	2
15	Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. <i>Cancer Investigation</i> , 2021, 39, 473-481.	0.6	9
16	An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome. <i>Turkish Journal of Haematology</i> , 2021, 38, 163-165.	0.2	3
17	Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. <i>Leukemia Research</i> , 2021, 107, 106586.	0.4	6
18	Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer. <i>Namık Kemal Tıp Dergisi</i> , 2021, 9, 179-183.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Severe Lymphocytosis in a Case with Diffuse Large B Cell Lymphoma Treated by Ibrutinib. Turkish Journal of Haematology, 2021, 38, 337-338.	0.2	1
20	Podocyte Injury in Cases with Newly Diagnosed Multiple Myeloma. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2021, 32, 722.	0.4	0
21	Prognostic and predictive value of EZH2 expression and the tumor immune microenvironment in Merkel cell carcinoma. Polish Journal of Pathology, 2021, 72, 140-147.	0.1	0
22	Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Journal of Cancer Education, 2020, 35, 69-75.	0.6	4
23	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
24	Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 244, 51-55.	0.5	7
25	Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Annals of Hematology, 2020, 99, 301-307.	0.8	4
26	Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 European Journal of Cancer Care, 2020, 29, e13296.	0.7	3
27	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer, 2020, 148, 48-54.	0.9	18
28	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e474-e484.	0.2	7
29	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576.	0.8	19
30	Prognosis Trend of Grade 2 Endometrioid Endometrial Carcinoma: Toward Grade 1 or 3?. Pathology and Oncology Research, 2020, 26, 2351-2356.	0.9	1
31	Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG). Indian Journal of Hematology and Blood Transfusion, 2020, 36, 640-645.	0.3	1
32	Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, 2020, 37, 104-107.	0.3	2
33	Cerebral MRI Mimicking Pachymeningeal Involvement Associated with Intrathecal Treatment. Turkish Journal of Haematology, 2020, 37, 308-309.	0.2	1
34	Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy. The Journal of Breast Health, 2020, 16, 229-234.	0.4	4
35	Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey. , 2020, , .		0
36	Obez endometrioid endometrial kanserli olgulara pelvik lenfadenektomiye paraaortik lenfadenektomi eklenmesinin saÄŸkalÄ±ma etkisi. Cukurova Medical Journal, 2020, 45, 134-140.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Meme kanserinde PRAME (preferentially expressed antigen of melanoma) ekspresyonunun prognostik önemi. Cukurova Medical Journal, 2020, 45, 1202-1209.	0.1	0
38	Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases. Turkish Journal of Haematology, 2020, 37, 220-225.	0.2	4
39	Dose-Adjusted R-EPOCH Therapy for Aggressive Lymphoma: A single center experience. Medical Science and Discovery, 2020, 7, 691-695.	0.1	0
40	Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). International Journal of Clinical Oncology, 2019, 24, 168-178.	1.0	25
41	Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable Response Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e242-e243.	0.2	1
42	Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. Biomarkers in Medicine, 2019, 13, 1565-1575.	0.6	29
43	Are Uterine Grade 3 Endometrioid Adenocarcinoma and Carcinosarcoma Really Clinically Similar?. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	0
44	Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. Archives of Gynecology and Obstetrics, 2019, 300, 377-382.	0.8	22
45	Orbital extramedullary leukaemia is not a rare entity. British Journal of Haematology, 2019, 186, e6-e7.	1.2	1
46	Management of adverse effects/toxicity of ibrutinib. Critical Reviews in Oncology/Hematology, 2019, 136, 56-63.	2.0	95
47	Pancreatic plasmacytoma: A rare but important entity for gastroenterologists, oncologists and hematologists. Journal of Oncological Science, 2019, 5, 109-111.	0.1	2
48	P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. Journal of Thoracic Oncology, 2019, 14, S558-S559.	0.5	3
49	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 2019, 83, 131-143.	1.1	8
50	Lokal ileri evre meme kanserli hastalarda neoadjuvan kemoterapinin ER, PR, c-erb2, VEGF ve Ki-67 üzerine etkisi. Cukurova Medical Journal, 2019, 44, 226-231.	0.1	2
51	Atypical Radiologic Image Characterized by Cavitory Lung Lesions in a Case of Hodgkin Lymphoma. Turkish Journal of Haematology, 2019, 36, 60-61.	0.2	1
52	Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, e16075-e16075.	0.8	1
53	Multiple myelomda kromozomal aberasyonlar: klinik sonuçlar ve bortezomib e yanıt. Cukurova Medical Journal, 2019, 44, 1-1.	0.1	0
54	Clinic, Prognostic and Predictive Value of Circulating Tumor DNA in Lymphomas. LLM Dergi, 2019, 3, 45-50.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Acute promyelocytic leukemia after anthracycline containing chemotherapy for breast cancer: Case report and review of the literature. <i>Journal of Oncological Science</i> , 2018, 4, 62-64.	0.1	1
56	PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. <i>Journal of Clinical Pathology</i> , 2018, 71, 637-641.	1.0	14
57	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature. <i>Journal of Oncological Science</i> , 2018, 4, 56-59.	0.1	2
58	Lymphocytic thyroiditis simulating thyroid cancer biochemically, radiologically and pathologically. <i>Journal of Oncological Science</i> , 2018, 4, 114-115.	0.1	0
59	Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 226, 25-29.	0.5	36
60	Tafro syndrome: Critical review for clinicians and pathologists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 88-95.	2.0	18
61	Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactive Iodine: A Case Report. <i>Balkan Medical Journal</i> , 2018, 35, 199-202.	0.3	3
62	EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e12584-e12584.	0.8	0
63	Merkel cell carcinoma in Turkey: A multicentric study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21591-e21591.	0.8	0
64	Plevral tutulumu olan plazma hücre neoplazisi. <i>Cukurova Medical Journal</i> , 2018, 43, 498-499.	0.1	0
65	Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1169-1173.	0.5	10
66	Coexistence of hypertrophic osteoarthropathy and myelofibrosis. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 472-474.	0.7	0
67	Primary central nervous system lymphoma: essential points in diagnosis and management. <i>Medical Oncology</i> , 2017, 34, 61.	1.2	23
68	Nivolumab for relapsed or refractory Hodgkin lymphoma: Experience in Turkey. <i>Hematological Oncology</i> , 2017, 35, 321-323.	0.8	0
69	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. <i>Annals of Oncology</i> , 2017, 28, 2496-2502.	0.6	60
70	Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. <i>Acta Orthopaedica Et Traumatologica Turcica</i> , 2017, 51, 1-6.	0.3	32
71	Evaluation of lipid profiles in patients treated with capecitabine. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 1206-1209.	0.4	5
72	Meta-analysis of the effect of rituximab in the treatment of primary central nervous system lymphoma. <i>Annals of Oncology</i> , 2017, 28, v112.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Super Scan Caused by Parathyroid Carcinoma Observed Both in 18F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 116-119.	0.3	4
74	Prevalence of cytogenetic abnormalities in chronic lymphocytic leukemia in the southern part of Turkey. <i>Indian Journal of Cancer</i> , 2017, 54, 572.	0.2	3
75	Effectiveness of bendamustine in relapse or refractory lymphoma cases: A report from Turkeyâ€™The Turkish Oncology Group (TOG) study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19027-e19027.	0.8	0
76	Oncologistsâ€™ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG). <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 3149-3155.	0.5	0
77	Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme. <i>Polish Journal of Pathology</i> , 2016, 4, 392-397.	0.1	8
78	Now is not the time to just talk, but to take action. <i>Journal of Oncological Science</i> , 2016, 1, xii.	0.1	0
79	Management of hemopoietic neoplasias during pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 52-64.	2.0	15
80	Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?. <i>Annals of Oncology</i> , 2016, 27, 1650-1651.	0.6	11
81	Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2016, 48, 2040-2045.	0.3	7
82	Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. <i>Medical Oncology</i> , 2016, 33, 93.	1.2	82
83	Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e347-e353.	0.9	6
84	Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 242-247.	0.5	39
85	Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables. <i>Medical Oncology</i> , 2016, 33, 34.	1.2	60
86	Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 145-146.	0.8	2
87	Systematic review/Meta-analysis The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. <i>Archives of Medical Science</i> , 2015, 4, 708-714.	0.4	22
88	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1545-1552.	0.8	73
89	PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 2015, 134, 199-207.	0.7	17
90	The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 923-929.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Hepatitis C virus and lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 246-256.	2.0	23
92	Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). <i>Breast Cancer</i> , 2015, 22, 480-485.	1.3	3
93	Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. <i>Annals of Hematology</i> , 2015, 94, 415-420.	0.8	27
94	DNA repair gene polymorphisms in B cell non-Hodgkin lymphoma. <i>Tumor Biology</i> , 2015, 36, 2155-2161.	0.8	10
95	<i>Helicobacter pylori</i> eradication in gastric diffuse large B cell lymphoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 3773.	1.4	28
96	Colchicine therapy in amyloidosis related with plasmacytic castlemans disease presenting with nephrotic syndrome. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2015, 26, 992.	0.4	3
97	Primitive uterine neuroectodermal tumours: Two case reports. <i>Türk Jinekoloji Ve Obstetrik Dernei Dergisi</i> , 2015, 12, 185-187.	0.3	6
98	A Unique Case of Merkel Cell Carcinoma with Ovarian Metastasis. <i>Balkan Medical Journal</i> , 2015, 31, 356-359.	0.3	6
99	The effect of platinum and docetaxel based chemoradiotherapy on survival in locally advanced unresectable non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18538-e18538.	0.8	0
100	Changes in PD-1 and PD-L1 Expression in Cases with Hodgkin Lymphoma after Chemotherapy. <i>Blood</i> , 2015, 126, 4998-4998.	0.6	0
101	Alterations of ghrelin with weights and correlation among ghrelin, cytokine and survival in patients receiving chemoradiotherapy for gastrointestinal cancers. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 876-82.	1.3	4
102	Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidylinositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9760-71.	0.5	3
103	The Role of Radiotherapy Among the Therapeutic Options for Castleman's Disease. <i>Turkish Journal of Haematology</i> , 2014, 31, 197-8.	0.2	3
104	Extramedullary Myeloid Tumor Involving the Pancreas: A Case Report and Review of the Literature. <i>Turkish Journal of Haematology</i> , 2014, 31, 295-300.	0.2	2
105	Prognostic importance of survivin, Ki-67, and topoisomerase II β in ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 393-398.	0.8	31
106	Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment. <i>Pharmacology</i> , 2014, 94, 183-189.	0.9	10
107	Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 242-247.	2.0	38
108	Abdominal actinomycosis with multiple myeloma: A case report. <i>Oncology Letters</i> , 2014, 8, 1876-1878.	0.8	4

#	ARTICLE	IF	CITATIONS
109	Pancreatic Carcinoma, Thrombosis and Mean Platelet Volume: Single Center Experience from the Southeast Region of Turkey. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9143-9146.	0.5	17
110	Programmed death-1 (PD-1) and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19514-e19514.	0.8	0
111	The evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11559-e11559.	0.8	0
112	Coarctation of the aorta diagnosed by physical examination after imaging. <i>Herz</i> , 2013, 38, 679-682.	0.4	0
113	Sweet's syndrome: A revisit for hematologists and oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 85-95.	2.0	47
114	Energy drinks and chemotherapy: Can these products cause detrimental effects in cancer patients receiving chemotherapy?. <i>European Journal of Internal Medicine</i> , 2013, 24, e3-e4.	1.0	0
115	Late Onset Epstein Barr Virus Seropositive Posttransplant Lymphoproliferative Disorder in Two Renal Transplant Receivers. <i>Turkish Journal of Haematology</i> , 2013, 30, 315-320.	0.2	1
116	A Case with Hypothyroidism Following Autologous Stem Cell Transplantation. <i>Turkish Journal of Haematology</i> , 2013, 30, 221-222.	0.2	0
117	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. <i>Turkish Journal of Haematology</i> , 2013, 30, 351-358.	0.2	14
118	Carbamazepine and Multiple Myeloma: Possible Interaction. <i>Turkish Journal of Haematology</i> , 2013, 30, 83-84.	0.2	5
119	The Permanent Improvement of Proteinuria and Renal Failure With Colchicine and Enalapril in a Leukemic Patient With Renal Amyloidosis Secondary to Ankylosing Spondylitis. <i>American Journal of Therapeutics</i> , 2013, 20, 344-346.	0.5	1
120	Sweet Syndrome in a Patient with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Curious Lymphocyte/Neutrophil Fluctuations. <i>Turkish Journal of Haematology</i> , 2013, 30, 413-415.	0.2	3
121	Coexistence of tuberous sclerosis complex and malignant melanoma. <i>Singapore Medical Journal</i> , 2013, 54, e233-5.	0.3	3
122	Social Support and Hopelessness in Patients with Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 571-578.	0.5	47
123	Social support and hopelessness in patients with breast cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 571-8.	0.5	19
124	Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases. <i>Pharmacology</i> , 2012, 90, 212-215.	0.9	17
125	Secondary malignancy after imatinib therapy: eight cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2012, 53, 1706-1708.	0.6	20
126	Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. <i>Medical Oncology</i> , 2012, 29, 2159-2165.	1.2	6

#	ARTICLE	IF	CITATIONS
127	Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia. <i>Medical Oncology</i> , 2012, 29, 2937-2943.	1.2	10
128	Adenosine deaminase activity in patients with ovarian neoplasms. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 155-159.	0.8	26
129	Retrospective Analysis of 498 Primary Soft Tissue Sarcomas in a Single Turkish Centre. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 4125-4128.	0.5	6
130	Commentary. <i>Journal of Neurosciences in Rural Practice</i> , 2012, 3, 100.	0.3	0
131	Epstein-Barr Virusâ€œPositive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. <i>Oncologist</i> , 2011, 16, 87-96.	1.9	99
132	Avascular Osteonecrosis and Accompanying Anemia, Leucocytosis, and Decreased Bone Mineral Density in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2011, 43, 863-866.	0.3	12
133	Bendamustine and rituximab is effective and cost-effective in older cases with aggressive lymphomas?. <i>Annals of Oncology</i> , 2011, 22, 2694-2695.	0.6	2
134	Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. <i>Leukemia Research</i> , 2011, 35, 340-345.	0.4	11
135	Hyponatremia Is Not a Rare Adverse Event in Bortezomib-Treated Patients. <i>Chemotherapy</i> , 2011, 57, 434-436.	0.8	9
136	PET CT imaging in extramedullary hematopoiesis and lung cancer surprise in a case with thalassemia intermedia. <i>Turkish Journal of Haematology</i> , 2011, 28, 60-62.	0.2	7
137	Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib. <i>Turkish Journal of Haematology</i> , 2011, 28, 232-234.	0.2	4
138	Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer. <i>Gaziantep Medical Journal</i> , 2011, 17, 67.	0.2	3
139	Anti-angiogenic strategies will be a revolution in lymphoma?. <i>Leukemia Research</i> , 2010, 34, 552.	0.4	2
140	Smudge cells: Very old history and new conclusions. <i>Leukemia Research</i> , 2010, 34, 1680.	0.4	2
141	Hepatitis C virus and lymphoma: which is useful--serum or tissue?. <i>Journal of Clinical Pathology</i> , 2010, 63, 1040-1040.	1.0	0
142	Stewart-Treves Syndrome: Questionable Response to Weekly Paclitaxel. <i>Chemotherapy</i> , 2010, 56, 66-68.	0.8	1
143	The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. <i>Nuclear Medicine Communications</i> , 2010, 31, 59-66.	0.5	18
144	Hairy Cell Leukemia and Bladder Cancer in a Patient: Relation with Dye Exposure and Review of the Literature. <i>Advances in Hematology</i> , 2009, 2009, 1-2.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?. <i>Leukemia Research</i> , 2009, 33, 566-567.	0.4	3
146	Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. <i>Leukemia Research</i> , 2009, 33, 1627-1635.	0.4	34
147	Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial. <i>Clinical Rehabilitation</i> , 2009, 23, 117-124.	1.0	73
148	Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. <i>European Journal of Internal Medicine</i> , 2009, 20, 96-99.	1.0	28
149	Castleman-like reaction due to toxic substance ingestion. <i>European Journal of Internal Medicine</i> , 2009, 20, 328-330.	1.0	3
150	Antioxidant enzyme levels in cases with gastrointesinal cancer. <i>European Journal of Internal Medicine</i> , 2009, 20, 403-406.	1.0	39
151	The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2009, 50, 366-373.	0.6	28
152	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. <i>Leukemia Research</i> , 2008, 32, 243-250.	0.4	14
153	Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2008, 32, 1424-1430.	0.4	40
154	SIADH induced by amiodarone in a patient with heart failure. <i>International Journal of Clinical Practice</i> , 2008, 62, 337-337.	0.8	9
155	Tailored thromboprophylaxis for patients with multiple myeloma treated by IMiDs. <i>Leukemia and Lymphoma</i> , 2008, 49, 1644-1645.	0.6	7
156	Motor Neuron Disease Associated with Multiple Myeloma. <i>International Journal of Neuroscience</i> , 2008, 118, 337-341.	0.8	4
157	Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. <i>Leukemia and Lymphoma</i> , 2007, 48, 389-395.	0.6	17
158	Gravin gene expression in acute leukaemias: Clinical importance and review of the literature. <i>Leukemia and Lymphoma</i> , 2007, 48, 1167-1172.	0.6	14
159	PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. <i>Leukemia Research</i> , 2007, 31, 365-369.	0.4	30
160	Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature. <i>Leukemia Research</i> , 2007, 31, 1495-1501.	0.4	25
161	Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. <i>Mycoses</i> , 2007, 50, 135-139.	1.8	9
162	Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2412-2413.	0.6	4

#	ARTICLE	IF	CITATIONS
163	Granulocytic sarcoma: 32 cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 2527-2541.	0.6	247
164	Transfusion-associated graft-versus-host disease. <i>European Journal of Internal Medicine</i> , 2006, 17, 151-156.	1.0	9
165	IDA-FLAG Regimen for the Therapy of Primary Refractory and Relapse Acute Leukemia: A Single-Center Experience. <i>American Journal of Therapeutics</i> , 2006, 13, 389-393.	0.5	28
166	Dramatic Improvement of Pulmonary Mucormycosis After Surgery in a Case Without Immunodeficiency. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 403-405.	0.1	4
167	Young age MDS: Differences between Western and Eastern countries. <i>Leukemia Research</i> , 2006, 30, 362.	0.4	16
168	Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia. <i>Leukemia Research</i> , 2006, 30, 364.	0.4	10
169	Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases. <i>Annals of Hematology</i> , 2006, 85, 63-63.	0.8	4
170	Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab. <i>Bone Marrow Transplantation</i> , 2005, 35, 317-318.	1.3	0
171	Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 277-277.	1.3	1
172	Hepatitis C virus infection and lymphomas. <i>International Journal of Cancer</i> , 2005, 113, 338-338.	2.3	0
173	PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospects. <i>American Journal of Hematology</i> , 2005, 79, 257-261.	2.0	66
174	VEGF-C expression in breast cancer: Clinical importance. <i>Advances in Therapy</i> , 2005, 22, 368-380.	1.3	12
175	Bilateral choroidal infiltration from indolent non-Hodgkin's lymphoma: A rapid course with poor prognosis. <i>Leukemia and Lymphoma</i> , 2005, 46, 615-617.	0.6	11
176	Glomerular Disease in Patients with Malignant Disease: Four Cases and Review of Literature. <i>Renal Failure</i> , 2005, 27, 1-6.	0.8	0
177	Granulocytic sarcoma of the heart: Extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. <i>Leukemia and Lymphoma</i> , 2005, 46, 1081-1084.	0.6	25
178	Different glomerulopathies accompanying non-small-cell lung cancer. <i>Mount Sinai Journal of Medicine</i> , 2005, 72, 279-81.	1.9	6
179	Prostatic Hypertrophy and Prostatic Infiltration in Small Lymphocytic Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 201-202.	0.6	3
180	Ovarian Granulocytic Sarcoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 183-185.	0.6	13

#	ARTICLE	IF	CITATIONS
181	Fludarabine-induced hemolytic anemia: successful treatment by rituximab. <i>The Hematology Journal</i> , 2004, 5, 81-83.	2.0	20
182	Lymphadenopathy in adult-onset Still's disease mimicking peripheral T-cell lymphoma. <i>Clinical Rheumatology</i> , 2004, 23, 81-82.	1.0	13
183	Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2004, 76, 252-257.	2.0	25
184	Scrotal ulceration associated with ATRA. <i>American Journal of Hematology</i> , 2004, 77, 206-207.	2.0	2
185	Fludarabine as the possible cause of acute myelofibrosis. <i>The Hematology Journal</i> , 2004, 5, 283-284.	2.0	2
186	Different glomerular pathologies in sickle cell anemia. <i>Clinical Nephrology</i> , 2004, 62, 400.	0.4	7
187	Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2004, 25, 1587-92.	0.5	2
188	Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2003, 74, 89-93.	2.0	24
189	Serous retinal detachment in a case with chronic lymphocytic leukemia: no response to systemic and local treatment. <i>Leukemia Research</i> , 2003, 27, 557-559.	0.4	15
190	Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: a possible relation with use of a tongue depressor. <i>American Journal of Medicine</i> , 2003, 114, 618-620.	0.6	15
191	Vasculitis Associated with All Trans Retinoic Acid (ATRA) in a Case with Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 547-548.	0.6	22
192	Extramedullary Relapse in the Pleura in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 189-191.	0.6	15
193	Hepatitis B Virus Reactivation During Fludarabine Therapy in Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 1249-1250.	0.6	6
194	Survivin and aven: two distinct antiapoptotic signals in acute leukemias. <i>Annals of Oncology</i> , 2003, 14, 1045-1050.	0.6	44
195	Granulomatous orchitis mimicking Hodgkin's lymphoma relapse. <i>The Hematology Journal</i> , 2003, 4, 370-371.	2.0	3
196	Prognostic Significance of Microvessel Density and Vascular Endothelial Growth Factor (VEGF) Expression in non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 2089-2093.	0.6	67
197	Successful Rituximab Therapy for Hemolytic Anemia Associated with Relapsed Splenic Marginal Zone Lymphoma with Leukemic Phase. <i>Leukemia and Lymphoma</i> , 2003, 44, 2165-2166.	0.6	20
198	Vascular Endothelial Growth Factor (VEGF) Expression in Plasmacytoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 139-143.	0.6	14

#	ARTICLE	IF	CITATIONS
199	Sickle Cell Anemia and Hematological Neoplasias. <i>Leukemia and Lymphoma</i> , 2002, 43, 1431-1434.	0.6	21
200	Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature. <i>American Journal of Hematology</i> , 2002, 70, 300-305.	2.0	133
201	Cutaneous lesions and chronic myelocytic leukemia (CML) in progression. <i>Annals of Hematology</i> , 2002, 81, 178-178.	0.8	0
202	HCV and tumors of the immune system. <i>Leukemia Research</i> , 2002, 26, 1141.	0.4	1
203	Granulomatous reaction after chemotherapy for Hodgkin's disease. <i>Leukemia Research</i> , 2002, 26, 967-970.	0.4	15
204	Chronic myeloid leukemia in a patient with colon adenocarcinoma. <i>Haematologia</i> , 2002, 32, 501-3.	0.2	6
205	MUC1 expression in plasmacytoma. <i>Leukemia Research</i> , 2001, 25, 221-225.	0.4	21
206	Primitive neuroectodermal tumor of the kidney: a rare entity. <i>International Urology and Nephrology</i> , 2001, 33, 449-451.	0.6	23
207	The Association of Thyrotoxicosis and Chronic Lymphoproliferative Disorders. <i>Leukemia and Lymphoma</i> , 2000, 38, 131-135.	0.6	3
208	Leukaemia cutis and leukaemic vasculitis. <i>British Journal of Dermatology</i> , 2000, 143, 773-779.	1.4	65
209	Sweet's syndrome accompanying leukaemia: seven cases and review of the literature. <i>Leukemia Research</i> , 2000, 24, 83-86.	0.4	42
210	Granulocytic sarcoma as the cause of giant abdominal mass: diagnosis by fine needle aspiration and review of the literature. <i>Leukemia Research</i> , 2000, 24, 267-269.	0.4	15
211	Vasculitis and Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 40, 105-112.	0.6	38
212	Postmastectomy Malignant Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 36, 417-420.	0.6	7
213	Lymphomatous Skin Infiltration at the Site of Previous Varicella Zoster Virus Infection in a Patient with T Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 37, 229-232.	0.6	7
214	Clinical significance and frequency of <i>Blastocystis hominis</i> in Turkish patients with hematological malignancy. <i>Acta Medica Okayama</i> , 2000, 54, 133-6.	0.1	49
215	Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. <i>British Journal of Cancer</i> , 1999, 80, 1303-1305.	2.9	35
216	Interesting morphologic finding in T-cell acute lymphoblastic leukemia. , 1999, 21, 55-56.		2

#	ARTICLE	IF	CITATIONS
217	All trans retinoic acid as the possible cause of necrotizing vasculitis. <i>Leukemia Research</i> , 1998, 22, 655-657.	0.4	23
218	p53 Protein Expression in Gastrointestinal Lymphomas. <i>Oncology</i> , 1997, 54, 84-87.	0.9	6
219	Younger age observation IN myelodysplastic syndrome. <i>Leukemia Research</i> , 1996, 20, 367.	0.4	11
220	p53 Protein Expression in Leukemias. <i>Acta Oncologica</i> , 1995, 34, 23-26.	0.8	3
221	An unusual amebic localization on the right hip. <i>Infection</i> , 1995, 23, 124-125.	2.3	1
222	Intracellular Glutathione Content in Leukemias. <i>Oncology</i> , 1995, 52, 112-115.	0.9	4
223	DNA ploidy, proliferative activity, and concanavalin A reactivity in breast cancer. <i>Journal of Surgical Oncology</i> , 1994, 56, 21-24.	0.8	1
224	Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1994, 15, 281-285.	0.6	8
225	Small cell carcinoma of the larynx. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1994, 15, 375-378.	0.6	10
226	Sweet's syndrome associated with G-CSF. <i>British Journal of Haematology</i> , 1993, 85, 191-192.	1.2	85
227	Megadose methylprednisolone pulse therapy in adult idiopathic thrombocytopenic purpura. <i>Lancet</i> , 1991, 337, 56.	6.3	36
228	Plasma Levels of Tumor Necrosis Factor Alpha during Hemodialysis. <i>Nephron</i> , 1991, 57, 477-478.	0.9	6
229	Ferritin levels in malignant effusions: a useful marker?. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 919.	0.9	4
230	Non-hodgkin's lymphomas in turkey. <i>Cancer</i> , 1988, 62, 1653-1657.	2.0	17
231	Analysis of breast cancer classification robustness with radiomics feature extraction and deep learning techniques. <i>Expert Systems</i> , 0, , .	2.9	2